Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
CGEN is in the medium-term up 58% in 1 year.
Description: Compugen Ltd., a therapeutic product discovery company, is engaged in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company?s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 fusion protein candidates for the treatment of autoimmune diseases and inflammatory conditions, such as multiple sclerosis and rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, CGEN-15022, and CGEN-15049; and CGEN-671, a novel antibody-drug conjugate. Compugen Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||ROE||ROI|
|Current Ratio||Quick Ratio||Long Term Debt/Equity||Debt Ratio|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||72.13 M||Cash From Investing Activities||-64.09 M||Cash From Operating Activities||-11.15 M||Gross Profit||130 K|
|Net Profit||-6.14 M||Operating Profit||-6.32 M||Total Assets||108.48 M||Total Current Assets||68.55 M|
|Total Current Liabilities||5.24 M||Total Debt||Total Liabilities||7.52 M||Total Revenue||510 K|
|High 52 week||4.49||Low 52 week||2.78||Last close||4.12||Last change||2.74%|
|RSI||48.86||Average true range||0.2||Beta||0.72||Volume||73.51 K|
|Simple moving average 20 days||-1.87%||Simple moving average 50 days||3.44%||Simple moving average 200 days||13.86%|
|Performance Week||-0.48%||Performance Month||-2.6%||Performance Quart||15.73%||Performance Half||11.96%|
|Performance Year||4.3%||Performance Year-to-date||35.53%||Volatility daily||2.67%||Volatility weekly||5.96%|
|Volatility monthly||12.22%||Volatility yearly||42.33%||Relative Volume||296.09%||Average Volume||206.53 K|
|New High||New Low|
2020-05-27 07:00:00 | Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
2020-05-20 07:02:00 | 2 Top Biotech Picks for May
2020-05-18 08:46:12 | Is the Options Market Predicting a Spike in Compugen CGEN Stock?
2020-05-13 09:48:01 | How Compugen CGEN Stock Stands Out in a Strong Industry
2020-05-08 14:39:51 | We're Not Very Worried About Compugen's NASDAQ:CGEN Cash Burn Rate
2020-05-08 10:52:02 | Top Ranked Momentum Stocks to Buy for May 8th
2020-05-06 22:00:47 | Compugen Ltd. CGEN Q1 2020 Earnings Call Transcript
2020-05-06 07:00:00 | Compugen Reports First Quarter 2020 Results
2020-05-04 11:57:09 | Can This Biotech Shed New Light on Cancer Immunotherapies?
2020-04-30 12:00:04 | Top Ranked Momentum Stocks to Buy for April 30th
2020-04-30 12:00:04 | Compugen CGEN is a Great Momentum Stock: Should You Buy?
2020-04-30 12:00:04 | What Makes Compugen CGEN a New Strong Buy Stock
2020-04-27 06:05:00 | Compugen sees "encouraging signals" from early-stage cancer trial
2020-04-24 10:50:51 | 3 Monster Growth Stocks Gearing up for Gains
2020-04-23 07:00:00 | Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020
2020-03-17 07:00:00 | Compugen Announces Closing of $75 Million Public Offering of Ordinary Shares
2020-03-12 06:05:00 | Compugen Announces Pricing of $75 Million Public Offering of Ordinary Shares
2020-03-11 16:01:00 | Compugen Announces Commencement of Public Offering of Ordinary Shares
2020-03-10 10:00:02 | Company News for Mar 10, 2020
2020-03-09 07:10:00 | Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
2020-02-20 07:05:00 | Compugen Reports Fourth Quarter and Full Year 2019 Results
2020-02-10 07:58:47 | Should You Worry About Compugen Ltd.'s NASDAQ:CGEN CEO Pay Cheque?
2020-02-04 07:00:00 | Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies
2020-01-16 19:47:18 | Compugen Stock Rebounds After Analyst Sees 60% Upside
2020-01-09 07:00:00 | Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones
2019-12-23 20:04:37 | Did Hedge Funds Drop The Ball On Compugen Ltd. CGEN ?
2019-12-20 07:00:00 | Compugen Added to the NASDAQ Biotechnology Index
2019-12-17 08:38:01 | 5 Biotech Stocks That Have More Than Doubled This Year
2019-12-11 09:04:02 | 5 Biotech Stocks Up More Than 100% This Year So Far
2019-12-11 05:31:08 | Compugen NASDAQ:CGEN Shareholders Have Enjoyed A 76% Share Price Gain
2019-12-03 12:00:05 | Are You Looking for a Top Momentum Pick? Why Compugen CGEN is a Great Choice
2019-11-11 07:00:00 | Compugen Reports Third Quarter 2019 Results
2019-11-05 08:06:00 | Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019
2019-11-04 07:00:00 | Compugen Announces FDA Clearance of IND Application for COM902
2019-10-28 07:00:00 | Compugen to Release Third Quarter 2019 Results on Monday, November 11, 2019